Skip to main content

Regen BioPharma Inc

corporate_fare Company Profile

Regen BioPharma Inc

RGBP·OTC·Life Sciences·CIK 0001589150

Regen, incorporated on April 24, 2012, focuses on developing regenerative medical applications. The company aims to license, internally develop, or acquire these applications up to the successful completion of Phase I and/or Phase II clinical trials. Following these trials, Regen plans to either sell or license the developed applications or advance them to Phase III clinical trials. The decision to proceed to Phase III is primarily based on a greater than anticipated indication of efficacy observed in Phase I trials. Currently, Regen has HemaXellarate in development. HemaXellarate is a cellular composition derived from a patient's own adipose (fat) tissue, containing endothelial progenitor cells and mesenchymal stem cells. The company believes that re-infusing HemaXellarate into a patient will regenerate their bone marrow and restore normal function. On February 5, 2013, Regen filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I clinical trial for HemaXellarate. This trial assesses HemaXellarate in patients with drug-refractory aplastic anemia. The Phase I trial's primary goals are to determine the safety and feasibility of intravenously administered autologous SVF cells in patients with severe, immune suppressive refractory aplastic anemia. Secondary goals include evaluating efficacy based on patients achieving a complete response, partial response, or relapse. On December 10, 2015, the FDA informed Regen that all clinical hold issues related to the HemaXellarate IND application were resolved, allowing the company to initiate the Phase I clinical trial.

Regen BioPharma Inc (OTC:RGBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for RGBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 10/10, with 7 rated 8 or above. Recent SEC coverage for RGBP spans 8-K, 10-Q, 1-A POS.

Recent high-impact activity:

  • Regen BioPharma Raises $112,500 Note and Signs $10M Discounted Equity Line With Coventry
  • Regen BioPharma Reports $239 Cash, Massive Dilution, and Going Concern Doubt
  • Regen BioPharma Discloses Dilutive Settlement, Auditor Change, and Super-Voting Preferred Stock
  • Regen BioPharma Reports Critical Cash Shortage, Massive Dilution, and Going Concern Doubt
  • Regen BioPharma Issues 77.8M Shares, Diluting Existing Holders by 36% to Settle Debt

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$236.56K
Net Income
-$1.27M
Diluted EPS
-$0.05
Op. Cash Flow
-$383.59K
Operating Income
-$338.54K
Cash & Equivalents
$69.56K
Debt / Equity
0.00×
Net Margin
-5.39×
Shares Outstanding
39.37M sh
Source: 10-K · filed 2025-12-30 · accession 0001493152-25-029526

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 86,197 shares in RGBP as of the October 30, 2026 settlement, a 37.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 98.2% of RGBP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)86,197 shares as of October 30, 2026
Change vs prior period▼ 37.9%
Days to cover1.00 at avg daily volume of 5,918,535
Daily short volume (FINRA facilities)98.2% of 23,092,523 shares on November 20, 2026
5-day average short volume95.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for RGBP, detected from its recent SEC filings · based on capital-structure filings through 2026-11-02.

Discounted Note and Equity Line Signed · Most Note Proceeds Retire Old Debt

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$0.0002
52-week range · as of 2026-11-02 $0.000001 – $0.0159
Market cap
$405.85K
Volume
23.1M (4.2× avg)
3-mo avg 5.5M
Live data · 2026-11-21 19:59 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RGBP - Latest Insights

RGBP
Nov 02, 2026, 6:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0001
Real-time Price: $0.0002 info
Change: +$0.0001 (+100%) info
Market Cap: $405.846K info
RGBP
Aug 17, 2026, 6:02 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0001
Real-time Price: $0.0002 info
Change: +$0.0001 (+100%) info
Market Cap: $405.846K info
RGBP
Jul 15, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.000155
Real-time Price: $0.0002 info
Change: +$0.000045 (+29%) info
Market Cap: $405.846K info
RGBP
May 14, 2026, 12:17 PM EDT
Filing Type: 10-Q
Importance Score:
10
Price at Filing: $0.0005
Real-time Price: $0.0002 info
Change: -$0.0003 (-60%) info
Market Cap: $405.846K info
RGBP
Mar 04, 2026, 2:49 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0010
Real-time Price: $0.0002 info
Change: -$0.0008 (-80%) info
Market Cap: $405.846K info
RGBP
Feb 13, 2026, 6:13 AM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.00147
Real-time Price: $0.0002 info
Change: -$0.00127 (-86%) info
Market Cap: $405.846K info
RGBP
Feb 02, 2026, 3:49 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0051
Real-time Price: $0.0002 info
Change: Stock Split info
Market Cap: $405.846K info
RGBP
Jan 21, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0060
Real-time Price: $0.0002 info
Change: Stock Split info
Market Cap: $405.846K info
RGBP
Jan 08, 2026, 1:00 PM EST
Filing Type: 1-A POS
Importance Score:
9
Price at Filing: $0.009762
Real-time Price: $0.0002 info
Change: Stock Split info
Market Cap: $405.846K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets